Last updated: 2026-10-12 06:59:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
BioStem Technologies, Inc. (BSEM) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $2.50, with a market capitalisation of $46.12M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.25 to $8.40. This page covers its latest market performance, valuation, price trends and company information.
$46.12M | |
$2.60 | |
$28.26 | |
$0.80 | |
$2.64 | |
64.61K | |
126.29K | |
-- | |
$8.40 | |
$2.25 | |
-- | |
-- |
BioStem Technologies, Inc. (BSEM) last closed at $2.64 as of 2026-10-09 23:31:00, unchanged from the previous close of $2.64.
During the latest regular trading session, BSEM traded between $0.80 and $28.26, with a volume of 64.61K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, BioStem Technologies, Inc. (BSEM) moved from $3.07 to $2.50, representing a decline of 18.44% ($0.57).
The stock traded between $2.36 and $3.24 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 130.02 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 4.1%
BSEM is currently trading at $2.50, placing it 4.1% of the way from its 52-week low of $2.25 to its 52-week high of $8.40. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 2 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of BioStem Technologies, Inc. (BSEM) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.